Optimizing Pneumococcal Vaccination Efforts in High-Risk Patients

Author(s):

Christina M. Madison, PharmD, FCCP, AAHIVPMary Barna Bridgeman, PharmD, BCPS, BCGP, FASCP

The key opinion leaders explore effective methods for educating patients about pneumococcal vaccination, highlighting its importance and benefits, while also addressing the impact of COVID-19 on vaccine hesitancy and potential fatigue in the general population.

EP: 1.Symptomatology and Transmission of Pneumococcal Infection

EP: 2.Manifestation of Pneumococcal Disease in Adults

EP: 3.High-Risk Populations for Severe Pneumococcal Infection

EP: 4.Patient Burden Associated with Pneumococcal Disease

EP: 5.Vaccination Efforts to Mitigate Pneumococcal Outbreaks

EP: 6.Comparing and Contrasting the Characteristics of the FDA-Approved Pneumococcal Vaccines

EP: 7.Target Patient Populations for Pneumococcal Vaccines

EP: 8.ACIP Recommendations for Pneumococcal Vaccination

EP: 9.Clinical Considerations for Pneumococcal Vaccination Scheduling

EP: 10.Clinical Data Supporting Pneumococcal Vaccination

EP: 11.Insights on Conjugate Pneumococcal Vaccines

EP: 12.Future Considerations for Pneumococcal Vaccination

EP: 13.Barriers to Administering Pneumococcal Vaccines and Best Practices for Overcoming Them

Now Viewing

EP: 14.Optimizing Pneumococcal Vaccination Efforts in High-Risk Patients

EP: 15.Closing Thoughts From The Panel On Pneumococcal Vaccination

What How can we engage with patients to educate and emphasize the need and benefits associated with immunizing against pneumococcal disease?
The COVID-19 pandemic has created a significant amount of vaccine fatigue and hesitancy. How do you identify these in your practice and how can they be overcome to achieve optimal vaccination rates?
What impact do social determinants such as racial and ethnic disparities have on the vaccination rates of pneumococcal vaccines in underserved populations (health equity vs. equality)?
What are the cost barriers that are present with pneumococcal vaccination and how can they be overcome?
What does good collaboration look like between stakeholders in an effort to vaccinate in underserved populations?